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Reduced Morbidity in the First Year After Initiating Highly
Active Antiretroviral Therapy Among Ugandan Adults
J. Mpendo, G. Miiro, C. Watera, P. Munderi, S. Nakubulwa,
I. Kaddu, D. Rutebarika ∗, J. Todd, H. Grosskurth
MRC/UVRI Uganda Research Unit, Entebbe, Uganda
Objective: To evaluate the effect of Highly Active Anti-
Retroviral Therapy (HAART) and cotrimoxazole prophylaxis
usage (CTX) on incidence of morbidity within the ﬁrst year
of HAART-eligibility.
Methods: Between July 1999 and April 2006, we collected
information on morbidity from an open cohort of HAART-
eligible patients (according to WHO criteria). We compared
morbidity among patients initiating HAART to morbidity
before the stepwise introduction of HAART and CTX. We used
available patients on HAART to select randomly a historical
group of HAART-na¨ıve but eligible patients who had propor-
tionally the same WHO stage and sex distribution. Patients
aged 16 years or older, visited the study team 6-monthly
and when ill. Patients’ demographics, WHO stage, HAART
status, CTX, any new morbidity event (disease, drug-related
and recurrent), haemoglobin and CD4 counts were collected
from the beginning of follow up to the ﬁrst year after initi-
ating HAART or becoming HAART-eligible. We estimated the
overall effect of HAART on morbidity; adjusted for the effect
of CTX by Mantel-Haenszel methods and adjusted for the
effect of other confounders by negative binomial regression.
Results: 219 HAART patients (median age 37 years;
73% women; 85% CTX; median Hb 11.7 g/dl and median
CD4 131 cells/ul) experienced 94 events. They contributed
127 Person-Years of Observations (PYOs). 616 HAART-na¨ıve
patients (median age 33 years; 70% women; 33% CTX; median
Hb 11.2 g/dl and median CD4 131 cells/ml) experienced 862
events. They contributed 474 PYOs. The overall morbidity
among HAART patients during their ﬁrst year of treatment
was 78% lower (HR = 0.22, 95% CI: 0.15—0.31) than the over-
all incidence among HAART-na¨ıve patients in unadjusted
analysis. CTX also had a protective effect against morbidity
(adjusted HR = 0.55, 95% CI: 0.38—0.79).
Conclusions: Morbidity reduced signiﬁcantly within the
ﬁrst year of initiating HAART in this setting. CTX had addi-
tional signiﬁcant protection against morbidity.
doi:10.1016/j.ijid.2008.05.503
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Background: A proportion of individuals who start highly
active antiretroviral therapy (HAART) fail to achieve ade-
quate CD4 cell reconstitution. We determined the frequency
and clinical signiﬁcance of suboptimal CD4 reconstitution
despite viral suppression (SO-CD4) in an urban HIV clinic in
Uganda, where patients initiate HAART with severe immun-
odeﬁciency.
Methods: We analyzed data from a prospective research
cohort of 559 patients initiating HAART between 04/04-
04/05 at the Infectious Diseases Institute, Kampala. We
deﬁned SO-CD4 as either of a) <50 CD4 cells/l increase
after 6 months of HAART, b) <100 cells/l increase after 12
months and c) <200 cells/l after 24 months. We assessed
the cumulative risk of adverse clinical events [death and
recurrent or new acquired immunodeﬁciency syndrome
(AIDS)-deﬁning illness] by Kaplan-Meier analysis.
Results: Of 559 patients initiating HAART, 386 (69%) were
female, with a median age of 38 years (IQR 33—34), and
CD4 count of 98 cells/l (IQR 21-163); 283 (51%) had a CD4
count <100 cells. 414 (74%) started D4T + 3TC +NVP while145
(26%) started ZDV + 3TC + EFZ. After 6, 12 and 24 months of
HAART, 380 (68%), 339(61%) and 309 (55%) had attained and
sustained viral suppression; of these, 78 (21%), 151 (45%) and
166(54%) respectively had SO-CD4; and 165(43%), 143(42%)
and 57(19%) remained with CD4 count 200 cells/l and
remained at signiﬁcant risk of life-threatening oppotunistic
infections. Our results highlight the need for strategies to
encourage early HIV diagnosis and timely initiation of HAART.
doi:10.1016/j.ijid.2008.05.504
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Background: The burden of HIV care in Uganda is enor-
mous and continues to increase rapidly. Existing HIV care
clinics are congested with increasing numbers of patients
seeking care and treatment. There’s an urgent need to roll
out ART to lower level health centers and decongest the
more established HIV clinics. We evaluated the effective-
ness of Antiretroviral therapy (ART) among adult patients
